Axsome Therapeutics, Inc. (AXSM) › Cash & EquivalentsAxsome Therapeutics, Inc. (AXSM) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2019: $219.97M2020: $183.88M2021: $86.47M2022: $200.84M2023: $386.19M2024: $315.35M2025: $322.93M$322.93M2019Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$322.93M+2.4%2024$315.35M-18.3%2023$386.19M+92.3%2022$200.84M+132.3%2021$86.47M-53.0%2020$183.88M-16.4%2019$219.97M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share